Verastem's RAMP 201 Data Shows Strong ORR/PFS Gains vs Conventional Care
VSTM has more than doubled off its 52-week low of $3.43.
Summary
Verastem reported new RAMP 201 molecular profiling and external control arm data showing avutometinib + defactinib significantly outperformed conventional care in recurrent low-grade serous ovarian cancer (LGSOC). In KRAS-mutant patients, ORR was 38.7% vs 0% for control, with median PFS of 22.1 months vs 6.5 months. KRAS wild-type patients also showed benefit (ORR 22.7% vs 7.9%, mPFS 11.3 vs 7.7 months), and triple wild-type tumors had an 18% ORR. A small Japanese cohort (n=16) showed 44% ORR, including 71% in KRAS-mutant. These data extend the evidence for the already FDA-accelerated approved combo in KRAS-mutant LGSOC and support potential label expansion to wild-type disease. The company faces going-concern risk and recently amended its Oberland facility, so positive clinical data are critical. Confirmatory Phase 3 RAMP 301 results and regulatory decisions will be key next steps.
At the time of this announcement, VSTM was trading at $7.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $715.5M. The 52-week trading range was $3.43 to $10.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.